Sonobird: Clinical trial on recurrent glioblastoma
Sonobird is an ongoing clinical trial* currently recruiting patients in Europe and the USA. It is evaluating the efficacy of using a combination of an implantable ultrasound device combined with chemotherapy comparison with standard-of care to treat recurrent glioblastoma.
What is the Sonobird trial?
Sonobird is a randomized, open-label, multicentric, two-arm pivotal trial comparing treatment with SonoCloud-9 combined with carboplatin versus standard of care lomustine or temozolomide in patients who are candidates for resection of their first glioblastoma recurrence.
Who can participate in the Sonobird Trial?
This trial is open to adult patients at first recurrence of glioblastoma after initial therapy, to whom doctors recommend a new partial or total tumor resection and chemotherapy.
What are the eligibility criteria?
Contacting a participating center
The Sonobird trial is currently recruiting patients in Europe and the United States of America. Find below the sites currently participating in the trial.
Contacting a participating center
About SonoCloud®
For a better understanding of how our medical device works, please visit the page dedicated to the ultrasound technology used in “SonoCloud®”. This device temporarily opens the blood-brain barrier to maximize the passage of chemotherapy into the brain, thereby potentially enhancing its effect against glioblastoma.
To meet the team behind the development of the SonoCloud®, please consult the “About Us” page. ». You’ll discover our history, our commitment and our achievements.